Skip to main content
Posters

Feasibility of Real-World Assessment of Patient-Reported Outcomes in Acute Myeloid Leukemia by Cytogenetic Risk and Treatment Status

By May 18, 2023No Comments
Poster: Real-World Pain Symptom Trajectory Among Multiple Myeloma Patients Under Remote Symptom Monitoring With Electronic Patient-Reported Outcomes (ePRO)

Authors: Nicholas C. Coombs, PhD, MSTAT1, Emily R. Beamon, PhD, MA, MPH11 Emelly Rusli, MPH2, Debra Wujcik, PhD2, Aaron Galaznik, MD2, and Tanya M. Wildes, MD, MSCI3

1 Piedmont Research Strategies
2 Carevive Systems, Inc.
3 University of Nebraska Medical Center

Objectives

  • Multiple Myeloma (MM) is a cancer where patients often experience pain due to osteolytic lesions.
  • Many patients receive treatment long-term, and symptom burden and quality of life are important to consider for patient well-being.
  • In this study, we used electronic patient-reported outcomes (ePRO) through a remote symptom monitoring program in MM patients experiencing variable levels of pain.

Methods

  • MM patients over age 18 currently on treatment were enrolled in the Carevive PROmpt® remote symptom monitoring program from March 1, 2021 to October 30, 2022.
  • All patients received baseline and weekly surveys assessing domains across symptom burden, physical function, frailty status, and overall health indicators.
  • Fourteen unique symptoms were assessed using items derived from the Patient-Reported Outcomes Version of the Common Technology Criteria for Adverse Events (PRO-CTCAE). Patients were followed through 16 weeks.

Results

  • A total of 49 patients were included in analysis.
  • For these patients, the average number of symptoms reported was 4.5, compared to 2.1 for those without baseline pain.
  • Both those with and without baseline pain experienced a reduction in average number of symptoms over time.
  • They were primarily male (63%) and White (80%) with a mean age of 68.6.
  • Nearly one-third of patients (n=13) reported baseline pain, which was severe in four cases.
  • However, those with baseline pain, on average, experienced at least one other co-occurring symptom throughout follow-up.

Conclusions

These findings suggest that patient experiences are comparable across variable levels of cytogenetic risk, prognosis severity and disease re-emergence. This may have bearing on treatment planning, particularly when weighing intensity of regimen. Although limited due to small sample sizes, results from this study underscore the value of routine follow-up, which should include PRO assessment throughout the entire therapeutic process.

 

Poster: Real-World Pain Symptom Trajectory Among Multiple Myeloma Patients Under Remote Symptom Monitoring With Electronic Patient-Reported Outcomes (ePRO)

Click image above to enlarge

Tags: